GRAL.US stock price

GRAIL

82.8 USD

-2.11 (-2.49%)

1MN

GRAL.US Key Statistics

Open price

84.81

High today

91.08

Low today

80.14

52 Week high

102.72

52 Week low

16.08

Trading hours

-12:00

-11:00

-10:00

-09:00

-08:00

-07:00

-06:00

-05:00

-04:00

-03:00

-02:00

-01:00

UTC 00:00

+01:00

+02:00

+03:00

+03:30

+04:00

+04:30

+05:00

+05:30

+05:45

+06:00

+07:00

+08:00

+09:00

+09:30

+10:00

+11:00

+12:00

+12:45

+13:00

+14:00

UTC 00:00

Symbol trading specification

Trade GRAIL

About GRAL.US

GRAIL (GRAL.US) stock price represents the market’s valuation of a pioneering biotech firm focused on early multi-cancer detection through blood-based testing.

What is GRAIL?

GRAIL is a public biotechnology company specializing in liquid biopsy technology, designed to detect a wide range of cancers at early stages via a simple blood draw. For those curious about how to trade GRAL.US on the SimpleFX platform, a demo account enables practicing trading scenarios using virtual funds, without any initial deposit. Trading on SimpleFX covers multiple equities, including those from the S&P500 index. Once switching to a live account, traders can apply leverage.

Current GRAL.US stock price

The GRAL.US stock price shows how Grail Inc. is valued, a healthcare company focusing on early cancer detection technologies. The GRAL.US live price can be checked on the SimpleFX website or Webtrader platform.

How does GRAIL work?

GRAIL’s business centers on its multi-cancer early detection test, combining DNA sequencing and machine learning to spot methylation markers in the bloodstream. Investors wondering how to invest in GRAL.US should understand that the company’s performance can be impacted by regulatory decisions, scientific test results, and commercial adoption rates. On SimpleFX, traders can diversify across global healthcare assets. Key factors influencing GRAIL’s stock price movements include clinical data outcomes, reimbursement policy changes, and broader biotech sector sentiment.

GRAL.US chart

The GRAL.US chart outlines Grifols ADR Class A’s price dynamics, supported by indicators that enable detailed technical evaluation. The Grifols chart may also be studied in a demo account providing the same features as the full version.

GRAIL stock price history

GRAIL, founded in 2015 and publicly listed in June 2024 following its spin-off from Illumina, has seen its stock price evolve alongside major milestones. Large GRAL’s stock price swings corresponded to trial outcomes, policy developments, and executive actions.

GRAL.US market cap

The GRAIL market cap helps traders gauge the company’s scale, funding stability, and standing within the biotech sector. Understanding GRAL’s market cap in relation to peer valuations can be instrumental when building or adjusting diverse portfolios.